###begin article-title 0
###xml 30 39 30 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 44 52 44 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
Investigating the role of the HLA-Cw*06 and HLA-DRB1 genes in susceptibility to psoriatic arthritis: comparison with psoriasis and undifferentiated inflammatory arthritis
###end article-title 0
###begin title 1
Objective:
###end title 1
###begin p 2
###xml 78 87 78 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 213 222 213 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 227 235 227 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
 Psoriasis of early onset (type I; age of onset ⩽40 years) is associated with HLA-Cw*06 while the shared epitope (SE) is associated with rheumatoid arthritis susceptibility. Our aim was to investigate the role of HLA-Cw*06 and HLA-DRB1 genes (including SE) with psoriatic arthritis (PsA) susceptibility.
###end p 2
###begin title 3
Methods:
###end title 3
###begin p 4
###xml 37 46 37 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 196 204 196 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 91 99 <span type="species:ncbi:9606">patients</span>
###xml 258 266 <span type="species:ncbi:9606">patients</span>
In a case-control association study, HLA-Cw*06 phenotype frequencies were compared between patients with PsA (n = 480), psoriasis alone (n = 611) and healthy controls (n = 166). Similarly, at the HLA-DRB1 locus, phenotype and SE frequencies were compared in patients with PsA (n = 480), early undifferentiated inflammatory arthritis alone (n = 1621) and healthy controls (n = 537).
###end p 4
###begin title 5
Results:
###end title 5
###begin p 6
###xml 4 13 4 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 98 101 98 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;21</sup>
###xml 191 194 191 194 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;13</sup>
###xml 279 290 279 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*07</italic>
###xml 323 332 323 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 439 450 439 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*04</italic>
###xml 112 120 <span type="species:ncbi:9606">patients</span>
###xml 210 218 <span type="species:ncbi:9606">patients</span>
###xml 359 367 <span type="species:ncbi:9606">patients</span>
The HLA-Cw*06 phenotype was associated with type I psoriasis (OR 6.9, 95% CI 4.4, 11.1, p = 2.2x10-21) and with patients with PsA having type I psoriasis (OR 5.0, 95% CI 3.2, 7.9, p = 4.39x10-13), but not with patients with PsA having type II psoriasis (age of onset >40 years). HLA-DRB1*07, in linkage disequilibrium with HLA-Cw*06, was also associated with patients with PsA having type I psoriasis (OR 2.7, 95% CI 2.1, 3.7, p<0.00001). HLA-DRB1*04 alleles and the SE were associated with undifferentiated inflammatory arthritis but not with PsA.
###end p 6
###begin title 7
Conclusions:
###end title 7
###begin p 8
###xml 42 51 42 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 56 67 56 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*07</italic>
###xml 88 96 <span type="species:ncbi:9606">patients</span>
###xml 206 214 <span type="species:ncbi:9606">Patients</span>
The SE is not a PsA susceptibility locus. HLA-Cw*06 and HLA-DRB1*07 are associated with patients with PsA having type I psoriasis, suggesting that the primary association is with age of onset of psoriasis. Patients with PsA having type I psoriasis, therefore, have a genetic background different to those with type II psoriasis, and adjustment for this is necessary in future studies that investigate the genetic susceptibility of PsA.
###end p 8
###begin p 9
###xml 162 163 162 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">1</xref>
###xml 298 299 293 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">2</xref>
###xml 299 300 294 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">3</xref>
###xml 862 871 857 866 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 924 925 919 920 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">4</xref>
###xml 925 926 920 921 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;</sup>
###xml 926 928 921 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13">13</xref>
###xml 1020 1024 1015 1019 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DRB1</italic>
###xml 1042 1046 1037 1041 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DRB1</italic>
###xml 1147 1149 1139 1141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">14</xref>
###xml 1149 1158 1141 1150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 442 447 <span type="species:ncbi:9606">human</span>
Psoriatic arthritis (PsA) is commonly defined as "an inflammatory arthritis (IA) associated with psoriasis, which is usually negative for rheumatoid factor (RF)".1 A strong genetic component to susceptibility is suggested by the sibling recurrence risk ratio (lambdas), which is estimated to be 27.23 Part of the genetic predisposition is likely to be explained by genes within the major histocompatibility complex (MHC) region. For example, human leucocyte antigen (HLA) associations with psoriasis and IA in the form of rheumatoid arthritis (RA) are well characterised and, in each case, the MHC genes involved are recognised as the major disease susceptibility locus. Psoriasis has two distinct ages of onset: type I, early onset disease occurring at ⩽40 years of age and type II, late onset occurring at >40 years of age. Carriage of the HLA class I allele, HLA-Cw*06 is associated with type I but not type II psoriasis.4-13 In contrast, RA is associated with carriage of the shared epitope (SE) of the HLA class II DRB1 gene (a group of DRB1 alleles sharing a conserved amino acid motif in the third hypervariable region of the DRbeta chain).14HLA-Cw*06 is not found on haplotypes encoding the SE.
###end p 9
###begin p 10
###xml 194 203 194 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 270 272 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
###xml 272 274 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">15</xref>
###xml 274 275 274 275 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;</sup>
###xml 275 277 275 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">19</xref>
###xml 306 310 306 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DRB1</italic>
###xml 339 350 339 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*07</italic>
###xml 414 425 414 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*04</italic>
###xml 517 519 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 519 520 519 520 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;</sup>
###xml 520 522 520 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26">26</xref>
###xml 543 551 543 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 559 572 559 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*0402</italic>
###xml 702 714 702 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB*0401</italic>
###xml 763 765 763 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27">27</xref>
###xml 824 835 824 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*02</italic>
###xml 837 847 837 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB*15</italic>
###xml 851 861 851 861 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB*16</italic>
###xml 956 958 956 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">28</xref>
###xml 958 960 958 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29">29</xref>
###xml 1074 1076 1074 1076 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">28</xref>
###xml 230 238 <span type="species:ncbi:9606">patients</span>
###xml 459 467 <span type="species:ncbi:9606">patients</span>
###xml 638 646 <span type="species:ncbi:9606">patients</span>
For PsA disease susceptibility, separating the HLA-related genetic contribution from the contribution to psoriasis and IA alone is a challenge. There is evidence to suggest that carriage of the HLA-Cw*06 allele is associated with patients with PsA with type I psoriasis.1215-19 Studies of the HLA class II DRB1 gene have reported that the HLA-DRB1*07 phenotype is associated with peripheral arthritis in PsA while HLA-DRB1*04 is associated with a subgroup of patients with PsA with polyarthritis mimicking that of RA.20-26 In one study of the HLA-DRB1 locus, HLA-DRB1*0402 (which is not a SE allele) was found to occur more frequently in patients with PsA compared with RA or healthy controls, whereas HLA-DRB*0401 (which is a SE allele) occurred less frequently.27 Conflicting results have been reported with regard to the HLA-DRB1*02 (HLA-DRB*15 or HLA-DRB*16) and PsA susceptibility with a decrease found in a UK study, but not in a cohort from Toronto.2829 More recently, a UK study showed no overall difference in the frequency of the SE between PsA cases and controls.28
###end p 10
###begin p 11
###xml 391 400 391 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 405 413 405 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 490 498 <span type="species:ncbi:9606">patients</span>
Of the associations reported, however, it is still unclear whether the primary association is with PsA itself or secondary to one of the two constituent components, ie, IA or psoriasis. In previous studies, all appropriate comparison groups have not been analysed and some studies have also lacked power to address this question. The aim of this study was to compare the association between HLA-Cw*06 and HLA-DRB1, including the SE, with PsA susceptibility by comparing these phenotypes in patients with PsA, early undifferentiated inflammatory arthritis (UIA) alone, psoriasis alone and healthy controls.
###end p 11
###begin title 12
METHODS
###end title 12
###begin title 13
Overview
###end title 13
###begin p 14
###xml 39 48 39 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 77 85 77 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 215 217 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30">30</xref>
###xml 219 220 219 220 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;</sup>
###xml 220 222 220 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33">33</xref>
###xml 297 306 297 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 463 471 463 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 487 498 487 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*04</italic>
###xml 500 511 500 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*07</italic>
###xml 513 524 513 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*02</italic>
###xml 526 536 526 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB*15</italic>
###xml 540 550 540 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB*16</italic>
###xml 65 73 <span type="species:ncbi:9606">patients</span>
###xml 105 113 <span type="species:ncbi:9606">patients</span>
###xml 398 406 <span type="species:ncbi:9606">patients</span>
###xml 598 606 <span type="species:ncbi:9606">patients</span>
###xml 703 711 <span type="species:ncbi:9606">patients</span>
###xml 915 923 <span type="species:ncbi:9606">patients</span>
For this study, we did not investigate HLA-Cw*06 carriage in UIA patients or HLA-DRB1 allele carriage in patients with psoriasis as previous studies have excluded a role for these genes in the respective conditions.1230-33 A case-control association study was performed to investigate the role of HLA-Cw*06 in determining susceptibility to PsA by comparing allele and phenotype frequencies between patients with PsA, psoriasis alone and healthy controls. For the HLA-DRB1 gene variants, HLA-DRB1*04, HLA-DRB1*07, HLA-DRB1*02 (HLA-DRB*15 or HLA-DRB*16) and SE phenotype frequencies were compared in patients with PsA, UIA alone and healthy controls. Stratification analyses were performed by subdividing patients with PsA into type I and type II psoriasis according to the age at onset of their skin disease (type I = age of onset ⩽40 years and type II = >40 years of age). Analyses were also repeated in subsets of patients with PsA stratified by the presence of RF.
###end p 14
###begin title 15
Subjects
###end title 15
###begin title 16
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients with psoriatic arthritis
###end title 16
###begin p 17
###xml 82 84 82 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34">34</xref>
###xml 19 27 <span type="species:ncbi:9606">patients</span>
###xml 95 103 <span type="species:ncbi:9606">patients</span>
###xml 274 282 <span type="species:ncbi:9606">patients</span>
###xml 462 470 <span type="species:ncbi:9606">patients</span>
The recruitment of patients with PsA for this study has been described previously.34 In brief, patients with PsA (n = 480) under active follow-up by hospital rheumatologists were recruited from throughout the UK with the majority of them coming from north-west England. All patients satisfied the inclusion criteria of having both clinically documented inflammatory synovitis and psoriasis regardless of their RF status. A trained research nurse interviewed the patients and completed a standardised clinical history and examination protocol. Detailed demographic and clinical information were obtained and whole blood was taken for the measurement of RF status, DNA extraction and subsequent genetic analysis.
###end p 17
###begin title 18
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients with psoriasis
###end title 18
###begin p 19
###xml 24 26 24 26 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35">35</xref>
###xml 27 35 <span type="species:ncbi:9606">patients</span>
###xml 179 187 <span type="species:ncbi:9606">patients</span>
As described previously,35 patients with type I psoriasis (age of onset ⩽40 years) (n = 611) were recruited via the Dermatology Centre at Hope Hospital in Manchester. Some of the patients with psoriasis may have an IA, but this was not documented for the majority. A subset (n = 229) underwent an examination to exclude inflammatory joint involvement.
###end p 19
###begin title 20
Undifferentiated inflammatory arthritis
###end title 20
###begin p 21
###xml 106 108 106 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36">36</xref>
###xml 333 341 333 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 185 193 <span type="species:ncbi:9606">Patients</span>
###xml 319 327 <span type="species:ncbi:9606">patients</span>
Patients with early UIA were recruited from the Norfolk Arthritis Register (NOAR) as described previously.36 This is a primary-care-based inception cohort of subjects with primary UIA. Patients were aged ⩾16 years with two or more inflamed peripheral joints lasting at least 4 weeks. For the purpose of this study, all patients with HLA-DRB1 data available were included (n = 1621).
###end p 21
###begin title 22
Population controls
###end title 22
###begin p 23
Control subjects without a history of IA or psoriasis were recruited from blood donors and general practice registers (n = 537).
###end p 23
###begin p 24
###xml 4 12 <span type="species:ncbi:9606">patients</span>
All patients and controls were white Caucasians of British descent. They were recruited with ethical committee approval (MREC 99/8/84 (PsA samples); LREC 00089 (psoriasis samples), LREC 2003-075 (NOAR samples)) and provided written informed consent.
###end p 24
###begin title 25
HLA typing
###end title 25
###begin p 26
###xml 27 33 27 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw</italic>
###xml 38 44 38 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR</italic>
###xml 157 163 157 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw</italic>
###xml 175 183 175 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 337 339 335 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34">34</xref>
Both broad HLA genotyping (HLA-Cw and HLA-DR) and subtyping to define SE alleles were performed using 50 ng of genomic DNA amplified with the Dynal RELI SSO HLA-Cw typing and HLA-DRB1 kits () using a third of the specified volumes for the polymerase chain reaction reagents in a 20 mul reaction instead of 60 mul as described previously.34 Alleles were assigned using the Pattern Matching Program provided by Dynal (Invitrogen Ltd, Paisley, UK).
###end p 26
###begin title 27
Statistical analysis
###end title 27
###begin p 28
###xml 37 46 37 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 122 123 120 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">2</xref>
Allele and phenotype frequencies for HLA-Cw*06 were compared between PsA cases, psoriasis cases and controls using the chi2 test implemented in STATA 8.
###end p 28
###begin p 29
###xml 8 16 8 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 22 33 22 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*04</italic>
###xml 35 71 35 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*07, HLA-DRB1*02 (HLA-DRB*15</italic>
###xml 75 85 75 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB*16</italic>
###xml 184 185 182 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">2</xref>
###xml 283 296 281 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*0101</italic>
###xml 298 311 296 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*0102</italic>
###xml 313 326 311 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*0104</italic>
###xml 328 341 326 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*0401</italic>
###xml 343 356 341 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*0404</italic>
###xml 358 371 356 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*0405</italic>
###xml 373 386 371 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*0408</italic>
###xml 391 404 389 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*1001</italic>
For the HLA-DRB1gene, HLA-DRB1*04, HLA-DRB1*07, HLA-DRB1*02 (HLA-DRB*15 or HLA-DRB*16) and SE phenotype frequencies were compared between cases with PsA, UIA and controls using the chi2 test implemented in STATA 8. The SE was defined by the presence of any of the following alleles: HLA-DRB1*0101, HLA-DRB1*0102, HLA-DRB1*0104, HLA-DRB1*0401, HLA-DRB1*0404, HLA-DRB1*0405, HLA-DRB1*0408 and HLA-DRB1*1001.
###end p 29
###begin p 30
###xml 32 40 <span type="species:ncbi:9606">patients</span>
The PsA cohort was divided into patients with type I and type II psoriasis by their age at onset of their psoriasis (⩽40 years or >40 years, respectively) and the analyses were repeated for each subset of PsA. Similar analysis was undertaken after stratifying the PsA cohort by their RF status.
###end p 30
###begin title 31
Linkage disequilibrium analysis
###end title 31
###begin p 32
###xml 60 61 60 61 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">2</xref>
###xml 89 98 89 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 103 114 103 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*07</italic>
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34">34</xref>
Pairwise linkage disequilibrium (LD) measures (both D' and r2) were investigated between HLA-Cw*06 and HLA-DRB1*07 using HelixTree (Golden Helix Inc, Bozenian, MT, USA). These data has been reported previously.34
###end p 32
###begin title 33
RESULTS
###end title 33
###begin p 34
###xml 38 47 38 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 52 60 52 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 85 92 85 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ARD-67-05-0677-t01">table 1</xref>
A summary of the samples used for the HLA-Cw*06 and HLA-DRB1 analysis is provided in table 1.
###end p 34
###begin title 35
Number of subjects in study (where data are available)
###end title 35
###begin p 36
UIA, early undifferentiated inflammatory arthritis; PsA, psoriatic arthritis; NA, not available.
###end p 36
###begin p 37
For three PsA cases, data were not available as to the type of psoriasis present.
###end p 37
###begin title 38
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient characteristics
###end title 38
###begin title 39
Psoriatic arthritis
###end title 39
###begin p 40
###xml 69 71 69 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34">34</xref>
###xml 731 733 731 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">19</xref>
###xml 733 735 733 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37">37</xref>
###xml 570 578 <span type="species:ncbi:9606">patients</span>
###xml 749 757 <span type="species:ncbi:9606">patients</span>
The characteristics of the PsA cohort have been described previously.34 There was an almost equal gender distribution with 57% being female and 74% having type I psoriasis. The median duration of psoriasis was 19 years (interquartile range (IQR) 9-33) and the median duration of joint disease was 10 years (IQR 5-19). A majority (63%) developed psoriasis before the onset of joint disease. RF was present in 17% (titre >1:40), 81% had nail involvement, 57% had five or more damaged joints (polyarthritis subgroup) and the median HAQ score was 1.25. As shown previously, patients with PsA with type I psoriasis have a stronger family history of both skin and joint disease and tend to develop arthritis after the onset of psoriasis.1937 In addition, patients with PsA with type I psoriasis had a longer duration of joint disease and more nail involvement, but a lower median HAQ score and fewer involved joints compared with those with type II psoriasis.
###end p 40
###begin title 41
Psoriasis
###end title 41
###begin p 42
###xml 395 404 395 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 542 551 542 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 147 155 <span type="species:ncbi:9606">patients</span>
###xml 285 293 <span type="species:ncbi:9606">patients</span>
###xml 447 455 <span type="species:ncbi:9606">patients</span>
All patients had type I psoriasis with 46% (283 of 611) being female. The median age of onset of psoriasis was 19 years (IQR 13-27). Some of these patients may have an unrecognised IA, but a subset (n = 229) have been specifically examined by a dermatologist to exclude an IA. All 611 patients with psoriasis were included in the analysis. No significant differences in clinical, demographic or HLA-Cw*06 carriage data were observed between those patients with psoriasis in whom PsA had been specifically excluded and those where it had not (HLA-Cw*06 carriage was 43% in those without PsA versus 40% in the remainder, p = 0.44).
###end p 42
###begin title 43
Early undifferentiated inflammatory arthritis
###end title 43
###begin p 44
###xml 244 246 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38">38</xref>
###xml 269 277 <span type="species:ncbi:9606">patients</span>
Within the UIA cohort, 1053 (65%) were female. At baseline, the median disease duration was 6 months (IQR 3-12); RF was present at a titre >1:40 in 452/1433 (31.5%) and 743 (48.3%) satisfied the American College of Rheumatology criteria for RA.38 By year 5, 11% of the patients were recorded to have psoriasis in addition to their IA and by year 10 of follow-up, 12% developed psoriasis.
###end p 44
###begin title 45
Controls
###end title 45
###begin p 46
###xml 115 124 115 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 160 168 160 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
In the population control cohort, gender information was available for 268 subjects of whom 119 (44%) were female. HLA-Cw*06 data were available for 166, while HLA-DRB1 data were available for 573 subjects.
###end p 46
###begin title 47
HLA-Cw*06
###end title 47
###begin p 48
###xml 21 30 21 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 136 138 136 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">15</xref>
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">16</xref>
###xml 140 142 140 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">25</xref>
###xml 142 144 142 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26">26</xref>
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b39">39</xref>
###xml 146 147 146 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;</sup>
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b41">41</xref>
###xml 151 158 151 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ARD-67-05-0677-t02">table 2</xref>
The frequency of the HLA-Cw*06 phenotype in the population controls tested in the current study was within the range reported previously1516252639-41 (table 2).
###end p 48
###begin title 49
###xml 14 23 14 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
Comparison of HLA-Cw*06 in PsA cases, psoriasis and controls
###end title 49
###begin p 50
###xml 34 42 <span type="species:ncbi:9606">patients</span>
###xml 84 92 <span type="species:ncbi:9606">patients</span>
PsA, psoriatic arthritis. Type I, patients with PsA with type I psoriasis; type II, patients with PsA with type II psoriasis.
###end p 50
###begin p 51
###xml 96 97 94 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">2</xref>
*Comparison of phenotype (carriage of one or two alleles) with population controls using the chi2 test.
###end p 51
###begin p 52
###xml 55 63 <span type="species:ncbi:9606">patients</span>
Data shown in n (%). Data were not available for three patients as to the type of psoriasis present.
###end p 52
###begin p 53
###xml 33 42 33 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 150 152 150 152 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;9</sup>
###xml 155 162 155 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ARD-67-05-0677-t02">table 2</xref>
###xml 167 172 167 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ARD-67-05-0677-f01">fig 1</xref>
###xml 331 333 331 333 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;9</sup>
###xml 366 375 366 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 485 488 485 488 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;13</sup>
###xml 408 416 <span type="species:ncbi:9606">patients</span>
###xml 514 522 <span type="species:ncbi:9606">patients</span>
When compared with controls, the HLA-Cw*06 phenotype was shown to be strongly associated with PsA (odds ratio (OR) 3.6, 95% CI 2.3, 5.8 and p = 5.5x10-9) (table 2 and fig 1). Stratification analysis in the PsA cohort by RF status made no difference to the result (OR in the RF-negative PsA subgroup 3.6, 95% CI 2.3, 5.9, p = 9.6x10-9). However, the association with HLA-Cw*06 was confined to the subgroup of patients with PsA with type I psoriasis (OR 5.0, 95% CI 3.2, 7.9, p = 4.39x10-13) and was not observed in patients with PsA with type II psoriasis (OR 1.1, 95% CI 0.6, 2.1, p = 0.76).
###end p 53
###begin title 54
Comparison of HLA-Cw*06 phenotype in psoriatic arthritis (PsA) cases, psoriasis and controls. Odds ratios and 95% confidence intervals are shown on a log scale.
###end title 54
###begin p 55
###xml 39 48 39 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 157 160 157 160 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;21</sup>
###xml 163 170 163 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ARD-67-05-0677-t02">table 2</xref>
###xml 175 180 175 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ARD-67-05-0677-f01">fig 1</xref>
###xml 204 213 204 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 289 298 289 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 582 591 582 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 629 635 629 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">per se</italic>
###xml 330 338 <span type="species:ncbi:9606">patients</span>
###xml 374 382 <span type="species:ncbi:9606">patients</span>
For the psoriasis cohort, as expected, HLA-Cw*06 was strongly associated with type I psoriasis compared with controls (OR 6.9 95% CI 4.4 to 11.1, p = 2.15x10-21) (table 2 and fig 1). To determine whether HLA-Cw*06 is associated with PsA itself or primarily with psoriasis, we compared the HLA-Cw*06 phenotype frequencies in those patients with PsA with type I psoriasis and patients with type I psoriasis alone. A much weaker association was noted (PsA with type I psoriasis versus type I psoriasis, OR 0.72, 95% CI 0.55, 0.96, p = 0.02), suggesting that the primary association of HLA-Cw*06 is with type I psoriasis and not PsA per se.
###end p 55
###begin title 56
HLA-DRB1
###end title 56
###begin p 57
###xml 40 51 40 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*07</italic>
###xml 209 220 209 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*07</italic>
###xml 363 372 363 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 388 389 388 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">2</xref>
###xml 399 401 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34">34</xref>
###xml 477 486 477 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 517 528 517 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*07</italic>
###xml 775 784 775 784 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 842 853 842 853 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*07</italic>
###xml 931 940 931 940 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 949 960 949 960 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*07</italic>
###xml 95 103 <span type="species:ncbi:9606">patients</span>
Stratification analysis showed that the HLA-DRB1*07 phenotype was strongly associated in those patients with PsA with type I psoriasis (OR 2.7, 95% CI 2.1, 3.7 and p<0.00001) compared with controls. Although, HLA-DRB1*07 occurred significantly more frequently in PsA cases than controls, we have previously reported that this allele exhibits considerable LD with HLA-Cw*06 (correlation (r2) = 0.46).34 Therefore, it was not unexpected that, after adjusting for the presence of HLA-Cw*06 phenotype, the association of HLA-DRB1*07 with PsA as a whole group (OR 1.38, 95% CI 0.88, 2.17, p = 0.16) or in the subgroup with type I psoriasis compared with controls (OR 1.63, 95% CI 0.96, 2.78, p = 0.07) was no longer statistically significant. However, the association of PsA with HLA-Cw*06 remained similar after adjusting for the presence of the HLA-DRB1*07 (OR 3.2, 95% CI 2.0 to 5.3), confirming that the primary association is with HLA-Cw*06 and not HLA-DRB1*07.
###end p 57
###begin p 58
###xml 64 75 64 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*04</italic>
###xml 322 333 322 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*04</italic>
###xml 610 621 610 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*04</italic>
###xml 935 946 935 946 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*04</italic>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 205 213 <span type="species:ncbi:9606">patients</span>
###xml 372 380 <span type="species:ncbi:9606">patients</span>
###xml 499 507 <span type="species:ncbi:9606">patients</span>
###xml 582 590 <span type="species:ncbi:9606">patients</span>
###xml 674 682 <span type="species:ncbi:9606">patients</span>
###xml 837 845 <span type="species:ncbi:9606">patients</span>
Patients with PsA negative for RF were less likely to carry the HLA-DRB1*04 phenotype compared with population controls (OR 0.74, 95% CI 0.55, 0.99, p = 0.03), but no difference was observed between those patients with PsA with a positive RF compared with controls (OR 0.96, 95% CI 0.56, 1.61, p = 0.88). In addition, the HLA-DRB1*04 phenotype occurred less frequently in patients with PsA with type I psoriasis compared with population controls (p = 0.004), but no difference was observed in those patients with PsA with type II psoriasis compared with controls (p = 0.45). Within patients with PsA, when the HLA-DRB1*04 phenotype was present, it occurred more commonly in patients with PsA with type II psoriasis compared with those with type I psoriasis (OR 1.81, 95% CI 1.14, 2.86, p = 0.007). No association was detected with those patients with PsA having ⩾5 damaged (poly-damaged) or ⩾5 involved (poly-involved) joints with the HLA-DRB1*04 phenotype compared with population controls (OR 0.87, 95% CI 0.6, 1.2, p = 0.39 and OR 0.81, 95% CI 0.60, 1.08, p = 0.14, respectively).
###end p 58
###begin p 59
###xml 0 7 0 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ARD-67-05-0677-t03">Table 3</xref>
###xml 42 53 42 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*04</italic>
###xml 159 170 159 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*07</italic>
###xml 288 290 288 290 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 445 456 445 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*04</italic>
###xml 464 475 464 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*07</italic>
###xml 606 617 606 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*04</italic>
###xml 725 736 725 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*07</italic>
###xml 317 325 <span type="species:ncbi:9606">patients</span>
###xml 544 552 <span type="species:ncbi:9606">patients</span>
###xml 775 783 <span type="species:ncbi:9606">patients</span>
Table 3 shows that in the UIA cohort, the HLA-DRB1*04 phenotype was more common than population controls (OR 1.40, 95% CI 1.14, 1.72 and p = 0.001), while the HLA-DRB1*07 phenotype was more common in the PsA cohort compared with population controls (OR 2.15, 95% CI 1.62, 2.84, p = 2.6x10-8). However, when comparing patients with PsA with type II psoriasis with UIA subjects, no difference was observed between these two cohorts for either the HLA-DRB1*04 or the HLA-DRB1*07 phenotypes (p = 0.35 and p = 0.45 respectively). When compared with patients with PsA with type I psoriasis, the frequency of the HLA-DRB1*04 phenotype was significantly higher in UIA subjects (OR 2.17, 95% CI 1.66, 2.84, p<0.0001). Conversely, the HLA-DRB1*07 phenotype was significantly higher in patients with PsA with type I psoriasis compared with UIA (OR 3.23, 95% CI 2.51, 4.14, p<0.0001).
###end p 59
###begin title 60
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
HLA-DRB1 phenotypes in PsA cases, UIA and controls (where data available)
###end title 60
###begin p 61
###xml 86 94 <span type="species:ncbi:9606">patients</span>
###xml 136 144 <span type="species:ncbi:9606">patients</span>
PsA, psoriatic arthritis; UIA, early undifferentiated inflammatory arthritis; type I, patients with PsA with type I psoriasis; type II, patients with PsA with type II psoriasis.
###end p 61
###begin p 62
Data shown in n (%) unless stated otherwise.
###end p 62
###begin p 63
###xml 70 81 70 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*02</italic>
###xml 83 93 83 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB*15</italic>
###xml 97 107 97 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB*16</italic>
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">28</xref>
###xml 204 206 204 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29">29</xref>
Previous studies have reported conflicting results with regard to the HLA-DRB1*02 (HLA-DRB*15 or HLA-DRB*16) and PsA susceptibility with a decrease found in a UK study, but not in a cohort from Toronto.2829 We did not observe a difference in our cohort.
###end p 63
###begin title 64
Shared epitope
###end title 64
###begin p 65
###xml 108 115 108 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ARD-67-05-0677-t04">table 4</xref>
###xml 120 125 120 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ARD-67-05-0677-f02">fig 2</xref>
###xml 15 23 <span type="species:ncbi:9606">patients</span>
###xml 191 199 <span type="species:ncbi:9606">patients</span>
###xml 340 348 <span type="species:ncbi:9606">patients</span>
###xml 461 469 <span type="species:ncbi:9606">patients</span>
When comparing patients with PsA and controls, no association was detected with SE allele carriage and PsA (table 4 and fig 2) either in the entire cohort (p = 0.94) or after stratifying the patients with PsA by type I or type II psoriasis or by their RF status. For example, no association was detected when comparing SE phenotype between patients with PsA with type I psoriasis and population controls (OR 0.90, 95% CI 0.68, 1.19, p = 0.43) or when comparing patients with PsA with type II psoriasis with population controls (OR of 1.24, 95% CI 0.82, 1.88, p = 0.28).
###end p 65
###begin title 66
Shared epitope phenotype in psoriatic arthritis (PsA) cases, undifferentiated inflammatory arthritis and controls. Odds ratios and 95% confidence intervals are shown on a log scale.
###end title 66
###begin title 67
Shared epitope frequency in PsA cases, UIA and controls
###end title 67
###begin p 68
###xml 86 94 <span type="species:ncbi:9606">patients</span>
###xml 136 144 <span type="species:ncbi:9606">patients</span>
UIA, early undifferentiated inflammatory arthritis; PsA, psoriatic arthritis; type I, patients with PsA with type I psoriasis; type II, patients with PsA with type II psoriasis.
###end p 68
###begin p 69
*Comparison of phenotype (carriage of one or two alleles) with population controls.
###end p 69
###begin p 70
Data shown in n (%) unless stated otherwise.
###end p 70
###begin p 71
###xml 121 124 121 124 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;10</sup>
###xml 126 133 126 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ARD-67-05-0677-t04">table 4</xref>
###xml 138 143 138 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ARD-67-05-0677-f02">fig 2</xref>
###xml 371 374 371 374 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;10</sup>
###xml 292 300 <span type="species:ncbi:9606">patients</span>
###xml 438 446 <span type="species:ncbi:9606">patients</span>
As expected, the SE was significantly associated with UIA compared with controls (OR 1.88, 95% CI 1.53, 2.29, p = 3.63x10-10; table 4 and fig 2). When comparing the UIA and PsA subgroups directly, the frequency of the SE phenotype was significantly higher in UIA subjects compared with those patients with PsA with type I psoriasis (OR 2.08, 95% CI 1.64, 2.66, p = 7.1x10-10), but the effect size was lower when comparing UIA subjects to patients with PsA with type II psoriasis (OR 1.51, 95% CI 1.02, 2.22, p = 0.03).
###end p 71
###begin title 72
DISCUSSION
###end title 72
###begin p 73
###xml 78 87 78 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 92 103 92 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*07</italic>
###xml 362 373 362 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*07</italic>
###xml 411 421 411 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06.</italic>
###xml 35 43 <span type="species:ncbi:9606">patients</span>
###xml 162 170 <span type="species:ncbi:9606">patients</span>
In this large association study of patients with PsA, we have shown that both HLA-Cw*06 and HLA-DRB1*07 are associated with PsA susceptibility in the subgroup of patients with PsA with type I psoriasis but not in those with type II psoriasis, suggesting that the primary association is with type I psoriasis. Our data also confirms that the association with the HLA-DRB1*07 is because this allele is in LD with HLA-Cw*06. We can find no evidence for association of the SE with PsA susceptibility.
###end p 73
###begin p 74
###xml 256 265 256 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 285 293 285 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 407 409 407 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
###xml 409 411 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30">30</xref>
###xml 411 412 411 412 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;</sup>
###xml 412 414 412 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33">33</xref>
###xml 480 489 480 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 494 505 494 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*07</italic>
###xml 575 577 575 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
###xml 577 579 577 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30">30</xref>
###xml 579 581 579 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31">31</xref>
###xml 581 583 581 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b42">42</xref>
###xml 655 666 655 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*07</italic>
###xml 700 709 700 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 736 745 736 745 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 68 76 <span type="species:ncbi:9606">patients</span>
###xml 273 281 <span type="species:ncbi:9606">patients</span>
###xml 297 305 <span type="species:ncbi:9606">patients</span>
###xml 435 443 <span type="species:ncbi:9606">patients</span>
###xml 759 767 <span type="species:ncbi:9606">patients</span>
###xml 791 799 <span type="species:ncbi:9606">patients</span>
The simultaneous investigation of two HLA genes in large cohorts of patients with PsA and appropriate control groups has enabled us to try and dissect out the contribution to PsA over and above that to UIA alone and psoriasis alone. We did not investigate HLA-Cw*06 in UIA patients or HLA-DRB1 in patients with psoriasis as previous studies have excluded a role for these genes in the respective conditions.1230-33 Previous studies on patients with psoriasis have shown that both HLA-Cw*06 and HLA-DRB1*07 are associated with type I psoriasis, but not with type II psoriasis.12303142 We have confirmed that, although both phenotypes show association, the HLA-DRB1*07 result has arisen due to LD with HLA-Cw*06. Furthermore, analysis of HLA-Cw*06 phenotype in patients with type I psoriasis, patients with PsA (stratified according to their types of psoriasis) as well as population controls has allowed us to conclude that the association is primarily with type I psoriasis rather than PsA itself.
###end p 74
###begin p 75
###xml 16 27 16 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*04</italic>
###xml 359 370 359 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*04</italic>
###xml 546 557 546 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*04</italic>
###xml 687 696 687 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR*07</italic>
###xml 237 245 <span type="species:ncbi:9606">patients</span>
###xml 290 298 <span type="species:ncbi:9606">patients</span>
###xml 386 394 <span type="species:ncbi:9606">patients</span>
###xml 479 487 <span type="species:ncbi:9606">patients</span>
###xml 727 735 <span type="species:ncbi:9606">patients</span>
Unsurprisingly, HLA-DRB1*04 was found to occur more frequently in the UIA cohort, the majority of whom satisfied American College of Rheumatology classification criteria for RA by 5 years. In contrast, it occurred less commonly in those patients with PsA who were negative for RF and those patients with PsA with type I psoriasis compared with controls. When HLA-DRB1*04 was present in patients with PsA, it occurred more frequently in those with type II psoriasis compared with patients with PsA with type I psoriasis. This may suggest that the HLA-DRB1*04 allele is protective for type I PsA. Alternatively, it may simply reflect the fact that if one allele is increased in frequency (HLA-DR*07 allele frequency increased in patients with PsA with type I psoriasis) then the frequency of others must be reduced.
###end p 75
###begin p 76
###xml 248 259 248 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*04</italic>
###xml 858 860 858 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b43">43</xref>
###xml 102 110 <span type="species:ncbi:9606">patients</span>
###xml 298 306 <span type="species:ncbi:9606">patients</span>
###xml 435 443 <span type="species:ncbi:9606">patients</span>
###xml 486 494 <span type="species:ncbi:9606">patients</span>
The broad inclusion criteria for PsA used in this study may have led to the misclassification of some patients who have true RA and coincidental psoriasis being classified as PsA. In this situation, one may have expected to see an association with HLA-DRB1*04 in either the RF-positive subgroup of patients with PsA or those with polyarticular disease but we did not find that to be the case. An advantage of not excluding RF-positive patients is that we have been able to stratify the patients with PsA by their RF status to explore whether RF is an important co-factor in PsA susceptibility. However, in no situation did this stratification change the conclusions of an analysis, suggesting that it is not. Our genetic findings, therefore, accord with recent clinical data suggesting that polyarticular PsA is more similar to oligoarticular PsA than to RA.43
###end p 76
###begin p 77
###xml 96 98 96 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">28</xref>
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29">29</xref>
###xml 253 261 <span type="species:ncbi:9606">patients</span>
###xml 316 324 <span type="species:ncbi:9606">patients</span>
###xml 498 506 <span type="species:ncbi:9606">patients</span>
###xml 576 584 <span type="species:ncbi:9606">patients</span>
###xml 673 681 <span type="species:ncbi:9606">patients</span>
###xml 722 730 <span type="species:ncbi:9606">patients</span>
We have also confirmed the finding of others that SE was not associated with PsA susceptibility.2829 Unsurprisingly, SE was found to be strongly associated with UIA susceptibility and occurred significantly more frequently in UIA subjects compared with patients with PsA with type I psoriasis. The smaller number of patients with PsA with type II psoriasis may have limited the interpretation of this analysis but the odds of carrying SE was also significantly higher in UIA subjects compared with patients with PsA with type II psoriasis. The findings confirm that, although patients with PsA with type II psoriasis appear more genetically similar to UIA subjects than do patients with PsA with type I psoriasis, UIA and patients with PsA with type II psoriasis are sufficiently different, in terms of their genetic susceptibility, to be viewed as distinct entities.
###end p 77
###begin p 78
###xml 69 78 69 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 145 154 145 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 273 282 273 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 401 412 401 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*07</italic>
###xml 455 464 455 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 511 522 511 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*02</italic>
###xml 524 535 524 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*04</italic>
###xml 537 548 537 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*07</italic>
###xml 658 667 658 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 671 679 671 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 837 846 837 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 1221 1230 1221 1230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-Cw*06</italic>
###xml 203 211 <span type="species:ncbi:9606">patients</span>
###xml 334 342 <span type="species:ncbi:9606">patients</span>
###xml 935 943 <span type="species:ncbi:9606">patients</span>
###xml 995 1003 <span type="species:ncbi:9606">patients</span>
###xml 1102 1110 <span type="species:ncbi:9606">patients</span>
###xml 1181 1189 <span type="species:ncbi:9606">patients</span>
###xml 1315 1323 <span type="species:ncbi:9606">patients</span>
In summary, our study confirms the established strong association of HLA-Cw*06 with type I psoriasis susceptibility. The association of PsA with HLA-Cw*06 is of similar strength and is confined to those patients with PsA with type I psoriasis. We conclude, therefore, that HLA-Cw*06 does not confer additional susceptibility to IA in patients with psoriasis. We also note that the association between HLA-DRB1*07 and PsA is due to its significant LD with HLA-Cw*06. No independent association was detected with HLA-DRB1*02, HLA-DRB1*04, HLA-DRB1*07 or with the SE and PsA. Our study suggests that the genetic susceptibility of PsA cannot be explained by the HLA-Cw*06 or HLA-DRB1 loci and confirms the importance of choosing the appropriate control populations when studying this condition. The findings also suggest that adjustment for HLA-Cw*06 is of central importance when attempting to dissect the genetic susceptibility of IA in patients with psoriasis. Finally, our findings suggest that patients with PsA with type I and type II psoriasis have different genetic susceptibility factors and that patients with PsA with type I psoriasis are more genetically similar to type I patients with psoriasis at least at the HLA-Cw*06 locus. This implies that in future genetic studies, it may be important to stratify patients with PsA according to the age of onset of psoriasis.
###end p 78
###begin p 79
This work has been supported by the Arthritis Research Campaign, the Wellcome Trust (Entry Level Fellowships for PYPCH and HSY; Advanced Fellowship for AB) and the Medical Research Council UK (Clinical Training Fellowship for PYPCH).
###end p 79
###begin title 80
REFERENCES
###end title 80
###begin article-title 81
Psoriatic arthritis.
###end article-title 81
###begin article-title 82
Familial occurrence of psoriatic arthritis.
###end article-title 82
###begin article-title 83
HLA is a candidate region for psoriatic arthritis. Evidence for excessive HLA sharing in sibling pairs.
###end article-title 83
###begin article-title 84
Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan.
###end article-title 84
###begin article-title 85
Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis.
###end article-title 85
###begin article-title 86
Genetics of psoriasis: paternal inheritance and a locus on chromosome 6p.
###end article-title 86
###begin article-title 87
Familial psoriasis and HLA-B: unambiguous support for linkage in 97 published families.
###end article-title 87
###begin article-title 88
Searching for psoriasis susceptibility genes in Italy: genome scan and evidence for a new locus on chromosome 1.
###end article-title 88
###begin article-title 89
Characterization of the major susceptibility region for psoriasis at chromosome 6p21.3.
###end article-title 89
###begin article-title 90
A genome-wide search for genes predisposing to familial psoriasis by using a stratification approach.
###end article-title 90
###begin article-title 91
Genomewide scan in German families reveals evidence for a novel psoriasis-susceptibility locus on chromosome 19p13.
###end article-title 91
###begin article-title 92
Evidence that HLA-Cw6 determines early onset of psoriasis, obtained using sequence-specific primers (PCR-SSP).
###end article-title 92
###begin article-title 93
Psoriasis and HLA-Cw6.
###end article-title 93
###begin article-title 94
Genetic approaches to the investigation of rheumatoid arthritis.
###end article-title 94
###begin article-title 95
Tumour necrosis factor-alpha polymorphism and the HLA-Cw*0602 allele in psoriatic arthritis.
###end article-title 95
###begin article-title 96
###xml 23 31 <span type="species:ncbi:9606">patients</span>
HLA-C locus alleles in patients with psoriatic arthritis (PsA).
###end article-title 96
###begin article-title 97
Association between HLA-BW38 and peripheral psoriatic arthritis.
###end article-title 97
###begin article-title 98
Histocompatibility antigens in psoriasis, psoriatic arthropathy, and ankylosing spondylitis.
###end article-title 98
###begin article-title 99
###xml 25 33 <span type="species:ncbi:9606">patients</span>
Immunogenetic profile of patients with psoriatic arthritis varies according to the age at onset of psoriasis.
###end article-title 99
###begin article-title 100
Psoriatic arthritis: clinical subgroups and histocompatibility antigens.
###end article-title 100
###begin article-title 101
Polymorphism in MICA rather than HLA-B/C genes is associated with psoriatic arthritis in the Jewish population.
###end article-title 101
###begin article-title 102
Histocompatibility typing in the seronegative spondyloarthropathies: a survey.
###end article-title 102
###begin article-title 103
Clinical and immunogenetic subsets of psoriatic arthritis.
###end article-title 103
###begin article-title 104
HLA class II and T cell receptor gene polymorphisms in psoriatic arthritis and psoriasis.
###end article-title 104
###begin article-title 105
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human lymphocyte antigens characterizing psoriatic arthritis and its subtypes.
###end article-title 105
###begin article-title 106
HLA antigens in psoriatic arthritis.
###end article-title 106
###begin article-title 107
HLA-DRB1*04 alleles in psoriatic arthritis: comparison with rheumatoid arthritis and healthy controls.
###end article-title 107
###begin article-title 108
The influence of the HLA-DRB1 rheumatoid arthritis shared epitope on the clinical characteristics and radiological outcome of psoriatic arthritis.
###end article-title 108
###begin article-title 109
HLA studies in psoriatic arthritis: current situation and future needs.
###end article-title 109
###begin article-title 110
Genetics of psoriasis.
###end article-title 110
###begin article-title 111
###xml 37 45 <span type="species:ncbi:9606">patients</span>
Analysis of HLA antigens in Croatian patients with psoriasis.
###end article-title 111
###begin article-title 112
A review of the MHC genetics of rheumatoid arthritis.
###end article-title 112
###begin article-title 113
Functional categorization of HLA-DRB1 alleles in rheumatoid arthritis: the protective effect.
###end article-title 113
###begin article-title 114
HLA-Cw6 and HLA-DRB1*07 together are associated with less severe joint disease in psoriatic arthritis.
###end article-title 114
###begin article-title 115
CARD15/NOD2 single nucleotide polymorphisms do not confer susceptibility to type I psoriasis.
###end article-title 115
###begin article-title 116
Evidence for common genetic control in pathways of inflammation for Crohn's disease and psoriatic arthritis.
###end article-title 116
###begin article-title 117
Clinical features of psoriatic arthritis according to the type of cutaneous ,psoriasis.
###end article-title 117
###begin article-title 118
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.
###end article-title 118
###begin article-title 119
HLA antigens in psoriatic arthritis subtypes of a Spanish population.
###end article-title 119
###begin article-title 120
HLA markers and progression in psoriatic arthritis.
###end article-title 120
###begin article-title 121
HLA antigens in psoriasis and psoriatic arthritis.
###end article-title 121
###begin article-title 122
The major psoriasis susceptibility locus PSORS1 is not a risk factor for late-onset psoriasis.
###end article-title 122
###begin article-title 123
Polyarticular psoriatic arthritis is more like oligoarticular psoriatic arthritis, than rheumatoid arthritis.
###end article-title 123
###begin p 124
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing interests:</bold>
Competing interests: None.
###end p 124

